FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1874298992> ?p ?o ?g. }

• W1874298992 endingPage "704" @default.
• W1874298992 startingPage "699" @default.
• W1874298992 abstract "We found that carrageenan (CAR), that is, sulfated polygalactose, can enhance both lipopolysaccharide (LPS)-induced tumor necrosis factor (TNF) production and the rate of lethality in mice (M. Ogata, S. Yoshida, M. Kamochi, A. Shigematsu, and Y. Mizuguchi, Infect. Immun. 59:679-683, 1991). It has been reported that platelet-activating factor (PAF) antagonists reduce the rate of mortality from endotoxin shock. However, there are few reports regarding the effect of PAF antagonists on TNF production. The aim of the present study is to examine the effect of TCV-309, a new PAF antagonist, on LPS-induced TNF production and mortality in mice pretreated with CAR. ddY mice (6 to 7 weeks old) were injected intraperitoneally with CAR (5 mg per mouse) and were then divided into two groups: mice treated with a PAF antagonist (TCV-309; Takeda Pharmaceutical Co.) and control mice. The mice treated with PAF antagonist received indicated doses of TCV-309 subcutaneously (s.c.) at 30 min before LPS injection, while the control mice received 1 ml of saline s.c. at the same time. All mice were stimulated by intravenous injection of LPS (50 micrograms per mouse) at 24 h after pretreatment with CAR. At intervals after injection of LPS, serum samples were obtained for a TNF assay in which cytotoxicity to L929 cells was measured. TCV-309 both significantly suppressed LPS-induced TNF production and reduced mortality in a dose-dependent manner. When TCV-309 was administered at 30 min before injection of LPS, the effect of TCV-309 on the suppression of TNF activity was at its peak. Treatment with TCV-309 (990 micrograms per mouse) s.c. significantly improved the survival rate after challenge with LPS compared with the survival rate of control mice. Although the 50% lethal dose of LPS was 15 micrograms per mouse for control mice, it increased to 102 micrograms per mouse for mice that were treated s.c. with TCV-309 (990 micrograms per mouse). Even in vitro, TCV-309 also inhibited LPS-induced TNF production in thioglycolate-elicited macrophages. It was concluded that PAF plays an important role in endotoxin-induced TNF production and mortality." @default.
• W1874298992 created "2016-06-24" @default.
• W1874298992 creator A5023370742 @default.
• W1874298992 creator A5027298906 @default.
• W1874298992 creator A5040745273 @default.
• W1874298992 creator A5071438979 @default.
• W1874298992 creator A5073066826 @default.
• W1874298992 creator A5074063536 @default.
• W1874298992 creator A5080684289 @default.
• W1874298992 creator A5082598030 @default.
• W1874298992 date "1993-02-01" @default.
• W1874298992 modified "2023-10-08" @default.
• W1874298992 title "An antagonist of platelet-activating factor suppresses endotoxin-induced tumor necrosis factor and mortality in mice pretreated with carrageenan" @default.
• W1874298992 cites W1861227972 @default.
• W1874298992 cites W1969719203 @default.
• W1874298992 cites W1979109569 @default.
• W1874298992 cites W1995422583 @default.
• W1874298992 cites W1999246265 @default.
• W1874298992 cites W1999797629 @default.
• W1874298992 cites W2004536137 @default.
• W1874298992 cites W2006887827 @default.
• W1874298992 cites W2017663495 @default.
• W1874298992 cites W2022274678 @default.
• W1874298992 cites W2037844521 @default.
• W1874298992 cites W2040180460 @default.
• W1874298992 cites W2065948470 @default.
• W1874298992 cites W2067219370 @default.
• W1874298992 cites W2086069132 @default.
• W1874298992 cites W2091309369 @default.
• W1874298992 cites W2092289140 @default.
• W1874298992 cites W2101720275 @default.
• W1874298992 cites W2107396956 @default.
• W1874298992 cites W2154686833 @default.
• W1874298992 cites W2336770370 @default.
• W1874298992 cites W2034636095 @default.
• W1874298992 doi "https://doi.org/10.1128/iai.61.2.699-704.1993" @default.
• W1874298992 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/302782" @default.
• W1874298992 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8423096" @default.
• W1874298992 hasPublicationYear "1993" @default.
• W1874298992 type Work @default.
• W1874298992 sameAs 1874298992 @default.
• W1874298992 citedByCount "33" @default.
• W1874298992 countsByYear W18742989922013 @default.
• W1874298992 countsByYear W18742989922014 @default.
• W1874298992 crossrefType "journal-article" @default.
• W1874298992 hasAuthorship W1874298992A5023370742 @default.
• W1874298992 hasAuthorship W1874298992A5027298906 @default.
• W1874298992 hasAuthorship W1874298992A5040745273 @default.
• W1874298992 hasAuthorship W1874298992A5071438979 @default.
• W1874298992 hasAuthorship W1874298992A5073066826 @default.
• W1874298992 hasAuthorship W1874298992A5074063536 @default.
• W1874298992 hasAuthorship W1874298992A5080684289 @default.
• W1874298992 hasAuthorship W1874298992A5082598030 @default.
• W1874298992 hasBestOaLocation W18742989921 @default.
• W1874298992 hasConcept C126322002 @default.
• W1874298992 hasConcept C134018914 @default.
• W1874298992 hasConcept C170493617 @default.
• W1874298992 hasConcept C17991360 @default.
• W1874298992 hasConcept C203014093 @default.
• W1874298992 hasConcept C2776885963 @default.
• W1874298992 hasConcept C2777928079 @default.
• W1874298992 hasConcept C2778122271 @default.
• W1874298992 hasConcept C2778754761 @default.
• W1874298992 hasConcept C2779020240 @default.
• W1874298992 hasConcept C2781227287 @default.
• W1874298992 hasConcept C71924100 @default.
• W1874298992 hasConcept C86803240 @default.
• W1874298992 hasConcept C98274493 @default.
• W1874298992 hasConceptScore W1874298992C126322002 @default.
• W1874298992 hasConceptScore W1874298992C134018914 @default.
• W1874298992 hasConceptScore W1874298992C170493617 @default.
• W1874298992 hasConceptScore W1874298992C17991360 @default.
• W1874298992 hasConceptScore W1874298992C203014093 @default.
• W1874298992 hasConceptScore W1874298992C2776885963 @default.
• W1874298992 hasConceptScore W1874298992C2777928079 @default.
• W1874298992 hasConceptScore W1874298992C2778122271 @default.
• W1874298992 hasConceptScore W1874298992C2778754761 @default.
• W1874298992 hasConceptScore W1874298992C2779020240 @default.
• W1874298992 hasConceptScore W1874298992C2781227287 @default.
• W1874298992 hasConceptScore W1874298992C71924100 @default.
• W1874298992 hasConceptScore W1874298992C86803240 @default.
• W1874298992 hasConceptScore W1874298992C98274493 @default.
• W1874298992 hasIssue "2" @default.
• W1874298992 hasLocation W18742989921 @default.
• W1874298992 hasLocation W18742989922 @default.
• W1874298992 hasLocation W18742989923 @default.
• W1874298992 hasOpenAccess W1874298992 @default.
• W1874298992 hasPrimaryLocation W18742989921 @default.
• W1874298992 hasRelatedWork W1861227972 @default.
• W1874298992 hasRelatedWork W1874298992 @default.
• W1874298992 hasRelatedWork W1976014549 @default.
• W1874298992 hasRelatedWork W1977918131 @default.
• W1874298992 hasRelatedWork W1990717759 @default.
• W1874298992 hasRelatedWork W2044718664 @default.
• W1874298992 hasRelatedWork W2065667368 @default.
• W1874298992 hasRelatedWork W2067143887 @default.
• W1874298992 hasRelatedWork W2103243613 @default.
• W1874298992 hasRelatedWork W2314693954 @default.

• next